Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nitroxyl donors are compounds that release nitroxyl (HNO), the one-electron reduced and protonated form of nitric oxide (NO). HNO is chemically distinct from NO, exhibiting unique biological activities. These donors have therapeutic potential in cardiovascular diseases like heart failure and hypertension, acting primarily through direct post-translational modification of thiol residues on target proteins. Examples include Angeli’s salt, Piloty’s acid, acyloxy nitroso compounds, BMS‐986231, and CXL-1020.
Releases nitroxyl (HNO) which modifies protein thiols, leading to vasodilation and improved cardiac function. Specifically, HNO reacts with cysteine residues to form N-hydroxysulfenamide intermediates and induces interdisulfide formation between specific cysteines on PKGIα kinase monomers, mimicking cGMP binding and activating PKGI without requiring cGMP itself.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nitroxyl Donor.